LLY – Eli Lilly and Company
Eli Lilly and CompanyLLY
$1,148.82Name : Eli Lilly and Company
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $1,024,008,781,824.00
EPSttm : 29.79
Eli Lilly and Company
$1,148.82
0.52%$5.97
LLY — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
0.89
Margin Of Safety %
Put/Call OI Ratio
1.14
EPS Next Q Diff
1.68
EPS Last/This Y
12.72
EPS This/Next Y
10.58
Price
1143.14
Target Price
1363.03
Analyst Recom
1.5
Performance Q
-4.73
Upside
-9.9%
Beta
0.43
Ticker: LLY
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-09-08 | LLY | 1123.91 | 1.13 | 1.20 | 354535 |
| 2026-09-09 | LLY | 1123.97 | 1.14 | 0.81 | 364343 |
| 2026-09-10 | LLY | 1122.77 | 1.14 | 0.79 | 369621 |
| 2026-09-11 | LLY | 1114.66 | 1.13 | 0.74 | 376340 |
| 2026-09-14 | LLY | 1137.64 | 1.15 | 0.73 | 355652 |
| 2026-09-15 | LLY | 1136.68 | 1.13 | 1.95 | 362786 |
| 2026-09-16 | LLY | 1138.38 | 1.17 | 1.00 | 372327 |
| 2026-09-17 | LLY | 1150 | 1.17 | 1.29 | 376540 |
| 2026-09-18 | LLY | 1152.79 | 1.16 | 0.84 | 380000 |
| 2026-09-21 | LLY | 1164.61 | 1.24 | 0.73 | 301464 |
| 2026-09-22 | LLY | 1168.01 | 1.20 | 0.66 | 310342 |
| 2026-09-23 | LLY | 1151.57 | 1.16 | 0.67 | 322740 |
| 2026-09-24 | LLY | 1183.79 | 1.16 | 0.61 | 329580 |
| 2026-09-25 | LLY | 1183.72 | 1.16 | 0.73 | 335207 |
| 2026-09-28 | LLY | 1185.69 | 1.19 | 0.67 | 308099 |
| 2026-09-29 | LLY | 1185.77 | 1.17 | 0.85 | 314709 |
| 2026-09-30 | LLY | 1159.3 | 1.17 | 0.62 | 319231 |
| 2026-10-01 | LLY | 1150.79 | 1.15 | 0.78 | 330289 |
| 2026-10-02 | LLY | 1143.71 | 1.14 | 0.84 | 336676 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-09-08 | LLY | 1123.78 | 40.6 | 10500.4 | 36.71 |
| 2026-09-09 | LLY | 1123.11 | 40.6 | 11556.2 | 36.71 |
| 2026-09-10 | LLY | 1122.70 | 40.6 | 11525.6 | 36.71 |
| 2026-09-11 | LLY | 1114.98 | 40.6 | 11241.4 | 36.71 |
| 2026-09-14 | LLY | 1138.19 | 40.6 | 12577.4 | 36.71 |
| 2026-09-15 | LLY | 1136.39 | 40.6 | 11509.4 | 36.71 |
| 2026-09-16 | LLY | 1136.39 | 40.6 | 11509.4 | 36.71 |
| 2026-09-17 | LLY | 1152.46 | 40.6 | 12221.4 | 36.73 |
| 2026-09-18 | LLY | 1152.70 | 40.6 | 11602.1 | 36.73 |
| 2026-09-21 | LLY | 1164.59 | 40.6 | 12086.7 | 36.73 |
| 2026-09-22 | LLY | 1170.46 | 40.7 | 12036.3 | 36.73 |
| 2026-09-23 | LLY | 1151.69 | 40.7 | 11024.6 | 36.73 |
| 2026-09-24 | LLY | 1183.19 | 40.7 | 13177.4 | 36.73 |
| 2026-09-25 | LLY | 1183.89 | 41.5 | 11884.2 | 36.91 |
| 2026-09-28 | LLY | 1185.98 | 41.5 | 17738.7 | 36.92 |
| 2026-09-29 | LLY | 1186.28 | 41.8 | 17696.2 | 36.93 |
| 2026-09-30 | LLY | 1159.45 | 41.8 | 10753.5 | 36.93 |
| 2026-10-01 | LLY | 1150.36 | 41.8 | 11514.9 | 36.93 |
| 2026-10-02 | LLY | 1143.14 | 41.8 | 11207.5 | 36.93 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-09-08 | LLY | -0.03 | -0.01 | 0.77 |
| 2026-09-09 | LLY | -0.03 | -0.01 | 0.77 |
| 2026-09-10 | LLY | -0.03 | -0.01 | 0.77 |
| 2026-09-11 | LLY | -0.03 | -0.01 | 0.93 |
| 2026-09-14 | LLY | -0.03 | -0.01 | 0.93 |
| 2026-09-15 | LLY | -0.03 | -0.01 | 0.93 |
| 2026-09-16 | LLY | -0.03 | -0.01 | 0.93 |
| 2026-09-17 | LLY | -0.03 | -0.01 | 0.93 |
| 2026-09-18 | LLY | -0.03 | -0.01 | 0.93 |
| 2026-09-21 | LLY | -0.03 | 0.00 | 0.93 |
| 2026-09-23 | LLY | -0.03 | 0.00 | 0.93 |
| 2026-09-24 | LLY | -0.03 | 0.00 | 0.93 |
| 2026-09-25 | LLY | -0.03 | 0.00 | 0.89 |
| 2026-09-28 | LLY | -0.03 | 0.01 | 0.89 |
| 2026-09-29 | LLY | -0.03 | 0.01 | 0.89 |
| 2026-09-30 | LLY | -0.03 | 0.01 | 0.89 |
| 2026-10-01 | LLY | -0.03 | 0.01 | 0.89 |
| 2026-10-02 | LLY | -0.03 | 0.01 | 0.89 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
8.38
Avg. EPS Est. Current Quarter
9.96
Avg. EPS Est. Next Quarter
10.06
Insider Transactions
-0.03
Institutional Transactions
0.01
Beta
0.43
Average Sales Estimate Current Quarter
22362
Average Sales Estimate Next Quarter
23341
Fair Value
1148.16
Quality Score
97
Growth Score
100
Sentiment Score
81
Actual DrawDown %
11.6
Max Drawdown 5-Year %
-34.5
Target Price
1363.03
P/E
38.85
Forward P/E
24.38
PEG
0.8
P/S
13.51
P/B
31.77
P/Free Cash Flow
59.17
EPS
29.43
Average EPS Est. Cur. Y
36.93
EPS Next Y. (Est.)
47.51
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
33.53
Relative Volume
0.8
Return on Equity vs Sector %
52.6
Return on Equity vs Industry %
43.3
EPS 1 7Days Diff
EPS 1 30Days Diff
0.22
EBIT Estimation
11207.5
◆
LLY
Healthcare
$1,143.30
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
43.1
Range 1M
30.8%
Sup Dist
0.3%
Momentum Growth
Ride accelerating trends
WATCH
EPS Yr
51.2%
EPS NY
28.1%
52W%
70.9%
Long-Term Value
Quality companies, undervalued
WATCH
🟡 HOLD
+26.7% upside
Upside
+26.7%
Quality
97
MoS
0%
LLY — P/E HistoricalDrug Manufacturers - General
Eli Lilly and CompanySector: Healthcare
Industry: Drug Manufacturers - General
Employees: 50000
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
LLY
Latest News
—
Caricamento notizie per LLY…
stock quote shares LLY – Eli Lilly and Company Stock Price stock today
news today LLY – Eli Lilly and Company stock forecast ,stock prediction 2023 2024 2025
marketwatch LLY – Eli Lilly and Company yahoo finance google finance
stock history LLY – Eli Lilly and Company invest stock market
stock prices LLY premarket after hours
ticker LLY fair value insiders trading